Search This Blog

Thursday, August 2, 2018

Amag Pharmaceuticals cuts FY18 revenue view to $525M-$565M from $540M-$580M


Consensus $540.26M. Raises FY18 adjusted EBITDA guidance to $125M-$145M from $120M-$140M.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)